Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av bortezomib, lenalidomid och dexametason (VRd) följt av BCMA CAR-T-terapi hos patienter som inte är berättigade till transplantation med primär plasmacellsleukemi (CAREMM-002)

Safety and Efficiency of VRd-based Regimen Combining BCMA CAR-T for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of treatment with VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia. Patients received 3-4 courses of induction therapy with VRD-based regimen followed by infusion of BCMA CAR-T cells. Patients then received 2-3 courses of consolidation therapy, followed by maintenance therapy.

Studietyp

Interventionell

Inskrivning (Beräknad)

20

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Tianjin, Kina
        • Rekrytering
        • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Age ≥ 18 years and ≤ 75 years.
  2. Participants with documented primary plasma cell leukemia according to IMWG diagnostic criteria (circulating plasma cells ≥5%, determined by morphology on peripheral blood smear; or absolute value of peripheral blood tumorigenic plasma cells exceeds 2×10^9/L).
  3. Measurable disease, at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or Light chain MM without measurable disease in serum or urine: serum Ig free-light chain (FLC) ≥10 mg/dL and abnormal serum Ig kappa lambda FLC ratio.
  4. Not considered for high-dose chemotherapy with Autologous Stem Cell Transplant (ASCT) due to: Ineligible due to advanced age (≥65); or Ineligible evaluated by researchers; or Eastern Cooperative Oncology Group Performance Status grade of 3 or 4; or Repeated hematopoietic stem cell mobilization failure; or Deferral of high-dose chemotherapy with ASCT as initial treatment.
  5. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.
  6. All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: a.TBIL<2 x upper limit of normal (ULN) (<3 x ULN in patients with Gilbert's syndrome); b.AST and ALT <3 x ULN.; c. Creatinine clearance ≥ 30mL/min (calculated using Cockroft-Gault formula).
  7. Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/platelet agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : WBC ≥ 1.5 x 109/L, ANC ≥ 1.0 x 109/L, Hb ≥ 70 g/L PLT ≥ 75 x 109/L (if BMPC < 50%) or PLT ≥ 50 x 109/L (if BMPC ≥ 50%).
  8. Patients must be able to take prophylactic anticoagulant therapy as recommended by the study.
  9. The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter.

Exclusion Criteria:

  1. Documented active amyloidosis.
  2. Documented with central nervous system (CNS) invasion.
  3. Prior exposure to any BCMA-targeted therapy or CAR-T therapy.
  4. Patients with peripheral neuropathy greater than grade 2 or peripheral neuropathy greater than grade 2 with pain at baseline, regardless of whether they were currently receiving medical therapy.
  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and BCMA-CART cellular products.
  6. Seropositive for human immunodeficiency virus (HIV)
  7. Hepatitis B infection
  8. Hepatitis C infection
  9. Life expectancy of <6 months
  10. Women who are pregnant or breastfeeding
  11. Any active gastrointestinal dysfunction that affects the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that may affect the absorption of the studied treatment medication
  12. Subjects had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period.
  13. Received live attenuated vaccine within 4 weeks prior to study treatment.
  14. According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing informed consent.
  15. Necessary medication or supportive therapy is contraindicated with study treatment.
  16. Any diseases or complications that may interfere with the study.
  17. Patients are not willing to or cannot comply with study scheme.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: VRD-based Regimen Combined With BCMA CART

VRD:Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle.

BCMA CAR-T products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg.

Participants will receive VRD-based induction, BCMA CAR-T infusion, consolidation, and maintenance.

Patients receive a single intravenous infusion of one of two BCMA-directed autologous CAR T-cell products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg.

Bortezomib, Lenalidomide and Dexamethasone

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Safety and Tolerability
Tidsram: Up to 2 year

The incidence of treatment-emergent adverse events (TEAEs)

Up to 2 year
MRD-negative rate
Tidsram: within 1 week after consolidation treatment

achieving MRD-negative, as determined by NGF after consolidation treatment

within 1 week after consolidation treatment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Complete response rate (CRR)
Tidsram: within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy

CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response accoording to the IMWG criteria

within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy
Progression free survival (PFS)
Tidsram: Up to 2 year

Progression free survival is defined as the time from the date of enrollment to the date of first documented PD, as defined in the IMWG criteria, or death due to any cause, whichever occurs first

Up to 2 year
Overall Survival (OS)
Tidsram: Up to 5 year

Overall survival is measured from the date of enrollment to the date of the participant's death.

Up to 5 year
Duration of Remission(DOR)
Tidsram: Up to 2 year

Duration of response is defined as the time from the first documented partial response (PR) or better to disease progression or death from any cause, whichever occurs first.

Up to 2 year

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The duration of CART cell in vivo
Tidsram: Up to 1 year

The copies of BCMA-CART DNA in peripheral blood with qPCR method

Up to 1 year
Change from Baseline in Physical status assessed by International Myeloma Working Group Comprehensive Geriatric Assessment (IMWG-CGA) scores
Tidsram: Baseline up to 5 years

The IMWG-CGA was calculated by combining age, activities of daily living (ADL), instrumental ADL (IADL), and Charlson Comorbidity Index (CCI), which ranges from 0 to 5 with higher scores indicating worse physical condition and greater weakness.

Baseline up to 5 years
Change from Baseline in Physical status assessed by activities of daily living (ADL) scores
Tidsram: Baseline up to 5 years

The ADL includes 4 items (transfer, bed mobility, toileting, and eating), which range from 0 to 6 scores. A higher score represents worse physical condition and greater weakness.

Baseline up to 5 years
Change from Baseline in Physical status assessed by instrumental activities of daily living (IADL) scores
Tidsram: Baseline up to 5 years

The IADL includes 5 items (cooking, cleaning, transportation, laundry, and managing finances), which range from 0 to 8 scores. A higher score represents worse physical condition and greater weakness.

Baseline up to 5 years
Change from Baseline in Physical status assessed by Charlson Comorbidity Index (CCI)
Tidsram: Baseline up to 5 years

The CCI estimates the number and the severity of comorbidities, including nineteen diseases with a score varying from 1 to 6 for each of them in accordance to their severity. The score can range from 0 to 37. A higher score represents more severe comorbidities.

Baseline up to 5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

14 augusti 2023

Primärt slutförande (Beräknad)

1 december 2026

Avslutad studie (Beräknad)

1 juli 2028

Studieregistreringsdatum

Först inskickad

29 juli 2023

Först inskickad som uppfyllde QC-kriterierna

29 juli 2023

Första postat (Faktisk)

7 augusti 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera